TIA-39-C20
WEIGHT MANAGEMENTQuick Specifications
| Vial Size | 24MG |
|---|---|
| BAC Water | 2.4ML |
| Amount Per Unit | 0.1MG PER UNIT |
| Recommended Dose | TITRATE UP FROM 2MG TO 12MG (20 TO 120 UNITS) |
| Frequency | 1X PER WEEK |
| Injection Type | SUBCUTANEOUS |
| Timing | Same Day Every Week / Starting Dose Is 2 MG — Titrate Very Slowly |
Research Overview
TIA-39-C20 (Triple Regulator) is a 39-amino acid triple incretin agonist belonging to the Peptide Receptor Modulator Research Series. It simultaneously activates three receptors: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). This triple mechanism adds glucagon receptor activation on top of dual incretin agonism — glucagon signaling directly increases resting energy expenditure and hepatic fat oxidation, producing weight loss effects beyond appetite suppression alone. Features a C20 fatty diacid (eicosanedioyl) side chain via a γ-Glu-2x AEEA linker for albumin binding and extended once-weekly half-life. CAS: 2381089-83-2. Structurally analogous in class to retatrutide. Once-weekly subcutaneous injection. Key reference literature: Jastreboff et al. (NEJM 2023) — triple-hormone-receptor agonist Phase 2 obesity trial (24.2% weight loss at 48 weeks); Sanyal et al. (Nature Medicine 2024) — retatrutide for MASLD; Rosenstock et al. (Lancet 2023) — Phase 2 retatrutide vs placebo.
Commonly Studied With
These peptides are frequently researched alongside Triple Regulator (TIA-39-C20): 24mg due to complementary mechanisms:
Triple Regulator (TIA-39-C20): 24mg information on this page is for research and educational purposes only. This content is not FDA-approved, does not constitute medical advice, and should not be used to guide personal health decisions. Consult a qualified healthcare professional before using any research compound.
Dose Calculator
Enter your target dose to calculate the volume to draw.
Recommended dose: TITRATE UP FROM 2MG TO 12MG (20 TO 120 UNITS)